BioCryst Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BioCryst Pharmaceuticals, Inc.
Marketing applications for 10 new drugs have been added to the latest list of products under review by the European Medicines Agency.
Gene therapy remains attractive when data show new technologies can advance the field, but gene regulation, editing and RNA therapies are grabbing investors’ attention, panelists said at ARM’s Cell and Gene Meeting on the Mesa.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Some remain unconvinced on durability, but CRISPR Therapeutics is looking at a second ‘consolidation’ dose and other measures to boost CTX110’s efficacy in a pivotal trial.
- Other Names / Subsidiaries
- BioCryst Pharmaceuticals